Diabetes can lead to many chronic complications, among which diabetic nephropathy is the most serious chronic complication of diabetes, and patients with uremia treated with dialysis in Europe, America and Japan are mainly due to diabetic nephropathy. At present, the second largest number of uremic patients receiving dialysis treatment due to diabetic nephropathy in our country, but the number of diabetic nephropathy patients entering dialysis increases rapidly every year. Before the reform and opening up, the prevalence of diabetes in China was very low, less than 1%, but in the past 30 years, the prevalence of diabetes in China has increased more than 10 times, because diabetic nephropathy is not formed in one day, it is generally believed that diabetic nephropathy may appear only after at least 5 years of diabetes, so with the progress of the disease process of so many new diabetic patients after the reform and opening up, diabetic nephropathy will appear an explosive Therefore, with the progress of the disease course of so many new diabetic patients after the reform and opening up, diabetic nephropathy will have an explosive growth process and will certainly become the primary cause of uremia in China. The traditional view that diabetic nephropathy will inevitably progress to uremia and that the goal of treatment is to slow down the progression of patients to uremia has been very disappointing to both patients and physicians. However, with the increase in the number of patients with diabetes mellitus combined with proteinuria, the depth of research and the accumulation of clinical experience of doctors, this traditional view may gradually change. Diabetic nephropathy can be divided into early diabetic nephropathy (microalbuminuria), clinical diabetic nephropathy (massive proteinuria), and late diabetic nephropathy (renal failure), and now some studies have found that some patients with early diabetic nephropathy can return to normal through active treatment, about half of them can stay in the microalbuminuria stage for a long time without progressing, and only a small proportion will gradually progress to Clinical proteinuria. On the one hand, some diabetic patients with large amounts of proteinuria may not be due to diabetic nephropathy alone, and some studies have found that the proportion of diabetic patients with other primary glomerular diseases does not differ from that of the non-diabetic population, and it is entirely possible for these patients to turn their proteinuria negative through active treatment. In my clinical observation, many patients with clinical diagnosis of diabetic nephropathy at the stage of clinical proteinuria have been followed up for nearly ten years and their renal function still remains normal. For the treatment of diabetic nephropathy, the main program of Western medicine is good control of blood glucose; secondly, good control of blood pressure, especially the choice of angiotensin-converting enzyme inhibitors or angiotensin receptor antagonist antihypertensive drugs that can reduce proteinuria and reduce glomerular hyperperfusion and hyperfiltration in patients with diabetic nephropathy; and the restriction of dietary protein intake after the occurrence of renal insufficiency, these three measures, but the efficacy of these measures is very limited. The efficacy of these measures is very limited, so more effective treatment options for diabetic nephropathy are being actively explored worldwide, however, because the pathogenesis of diabetic nephropathy is very complex, it now seems that the study of therapeutic drugs for diabetic nephropathy from a single so-called specific mechanism often proves effective in animal trials, but once clinical trials are conducted in humans they all fail because of ineffectiveness or significant toxic side effects The drugs have failed. In China, there are many clinical observational reports found that Reglanthoside, which is used for the treatment of chronic glomerulonephritis, can significantly reduce proteinuria in patients with diabetic nephropathy, and I have applied this drug in clinical practice. The long-term efficacy and why it is effective in some patients but not in others need to be further studied. Chinese medicine is a treasure trove of medicine in China, but since its mechanism of action cannot be fully explained by current modern biological techniques and theories, and there is a lack of clinical research methods to verify its effectiveness according to Western standards (the essence of Chinese medicine is evidence-based treatment and individualized treatment, while modern medicine requires homogeneity and standardization), it is still under intense debate as to whether Chinese medicine can effectively prevent and treat diabetic nephropathy and stop its progression to uremia. However, many animal experiments and small clinical observations (most of which do not meet the standards of evidence-based medical research required by modern medicine) suggest that many Chinese medicines are effective in treating diabetic nephropathy, and my long-term clinical experience, as well as the results of experimental studies of several NSF-funded projects that I chaired, tell me that Chinese medicine must be effective in treating diabetic nephropathy. I am committed to applying the combination of Chinese and Western medicine in the treatment of diabetic nephropathy, taking advantage of the respective strengths of Chinese medicine and Western medicine, and complementing their weaknesses to contribute what I can to the exploration of the combination of Chinese and Western medicine in the prevention and treatment of diabetic nephropathy. However, I think that in the process of exploring a difficult disease, we actually need the participation of patients, and I always believe that patients are the teachers of doctors, so I very much welcome patients with diabetic nephropathy to join our research team to fight together to overcome this disease that seriously threatens the health of our people. A few days ago, I established a “Diabetic Nephropathy Patient Management WeChat Group” with our team of doctors to gradually include our diabetic nephropathy patients in this group, and I hope that more new patients will join it. The purpose of establishing this group is to provide medical help to patients through our doctors, and to develop specific medical plans according to patients’ conditions, so that we can follow up the patients for a long time and observe their conditions through 5, 10 or 20 years, and patients can also communicate with each other to explore the best treatment plan that meets the specific conditions of each patient.